The startup develops immunomodulatory biologic therapeutics that utilize a tissue-engineered heart graft with multiple cell types to enhance blood flow in damaged heart tissues. This technology aims to improve cardiac function in patients suffering from muscle-related diseases and injuries.
Funding
$530K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Heart failure, a leading cause of death, often results from damaged heart tissues that lack sufficient blood flow. Current treatments do not fully restore cardiac function in patients suffering from muscle-related diseases and injuries.
Solution
Avery Therapeutics is developing immunomodulatory biologic therapeutics designed to redirect the immune system and restore organ function in patients with diseases of aging, inflammation, and fibrosis. Their lead program focuses on a tissue-engineered heart graft with multiple cell types to enhance blood flow in damaged heart tissues. This adaptive biologic platform aims to improve cardiac function and overall quality of life by addressing the underlying causes of heart failure. The therapy leverages the body's own immune system to promote tissue repair and regeneration.
Target Audience
The primary target audience includes patients suffering from heart failure and other muscle-related diseases and injuries, as well as the healthcare providers who treat them.
Features
- Immunomodulatory approach to redirect the immune system for tissue repair
- Tissue-engineered heart graft with multiple cell types
- Biologic platform designed to address diseases of aging, inflammation, and fibrosis
- Focus on restoring organ function and improving quality of life